| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1734-1140(10)70371-6 |
| P698 | PubMed publication ID | 21273666 |
| P50 | author | Bogusław Okopień | Q57089603 |
| Robert Krysiak | Q90104244 | ||
| Anna Gdula-Dymek | Q114411353 | ||
| P2860 | cites work | Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation | Q43600847 |
| Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease | Q44071017 | ||
| Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia | Q46198283 | ||
| Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus | Q46266485 | ||
| Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. | Q46724170 | ||
| Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. | Q46955983 | ||
| Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. | Q51468245 | ||
| Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? | Q51479251 | ||
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study | Q31829404 | ||
| Do HMG-CoA reductase inhibitors affect fibrinogen? | Q32052986 | ||
| Role of oxidized LDL in atherosclerosis | Q34496952 | ||
| Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents | Q34986710 | ||
| Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes | Q35200997 | ||
| Role of thrombotic and fibrinolytic factors in acute coronary syndromes | Q35821377 | ||
| Pathobiology of atherosclerosis--a brief review | Q35998975 | ||
| Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management | Q36320560 | ||
| Overview of hemostatic factors involved in atherosclerotic cardiovascular disease | Q36396260 | ||
| Pleiotropic effects of statins--clinical evidence | Q37387536 | ||
| Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications | Q37512877 | ||
| Markers of inflammation and risk of coronary heart disease. | Q37601853 | ||
| Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. | Q37605536 | ||
| Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances | Q43111569 | ||
| Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. | Q43191754 | ||
| P433 | issue | 6 | |
| P921 | main subject | simvastatin | Q670131 |
| P304 | page(s) | 1090-1098 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Pharmacological Reports | Q15766499 |
| P1476 | title | Hemostatic effects of simvastatin in subjects with impaired fasting glucose | |
| P478 | volume | 62 |
| Q43447250 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance |
| Q37898699 | Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia |
| Q51355302 | Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose. |
| Q51369235 | Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients. |
| Q46210874 | Statins suppress glucose-induced plasminogen activator inhibitor-1 expression by regulating RhoA and nuclear factor-κB activities in cardiac microvascular endothelial cells |
Search more.